Go Pro
NASDAQ:IRMD

iRadimed (IRMD) Stock Price, News & Analysis

iRadimed logo
$97.03 0.00 (0.00%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$97.04 +0.02 (+0.02%)
As of 07:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About iRadimed Stock (NASDAQ:IRMD)

Advanced

Key Stats

Today's Range
$96.14
$98.46
50-Day Range
$84.75
$102.30
52-Week Range
$55.11
$107.90
Volume
75,919 shs
Average Volume
131,591 shs
Market Capitalization
$1.24 billion
P/E Ratio
53.02
Dividend Yield
0.82%
Price Target
$120.00
Consensus Rating
Buy

Company Overview

iRadimed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

IRMD MarketRank™: 

iRadimed scored higher than 48% of companies evaluated by MarketBeat, and ranked 507th out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    iRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    iRadimed has a consensus price target of $120.00, representing about 23.7% upside from its current price of $97.03.

  • Amount of Analyst Coverage

    iRadimed has only been the subject of 1 research reports in the past 90 days.

  • Read more about iRadimed's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of iRadimed is 53.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.01.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of iRadimed is 53.02, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.07.

  • Price to Book Value per Share Ratio

    iRadimed has a P/B Ratio of 13.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about iRadimed's valuation and earnings.
  • Percentage of Shares Shorted

    8.21% of the float of iRadimed has been sold short.
  • Short Interest Ratio / Days to Cover

    iRadimed has a short interest ratio ("days to cover") of 4.85.
  • Change versus previous month

    Short interest in iRadimed has recently increased by 0.62%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    iRadimed has a dividend yield of 0.82%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    iRadimed has only been increasing its dividend for 1 years.

  • Dividend Coverage

    The dividend payout ratio of iRadimed is 43.72%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about iRadimed's dividend.
  • News Sentiment

    iRadimed has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for iRadimed this week, compared to 3 articles on an average week.
  • Search Interest

    Only 3 people have searched for IRMD on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, iRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,398,103.00 in company stock.

  • Percentage Held by Insiders

    34.60% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about iRadimed's insider trading history.
Receive IRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iRadimed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRMD Stock News Headlines

Analysts Set iRadimed Corporation (NASDAQ:IRMD) PT at $120.00
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
IRadimed Rides 3870 Momentum Despite Near-Term Dip
Iradimed Corp Eyes 2026 Surge After Strong Quarter
See More Headlines

IRMD Stock Analysis - Frequently Asked Questions

iRadimed's stock was trading at $97.28 at the beginning of the year. Since then, IRMD stock has decreased by 0.3% and is now trading at $97.03.

iRadimed Corporation (NASDAQ:IRMD) announced its earnings results on Friday, May, 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.46 by $0.03. The medical equipment provider earned $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed had a trailing twelve-month return on equity of 24.48% and a net margin of 27.36%.
Read the conference call transcript
.

iRadimed (IRMD) raised $13 million in an initial public offering on Wednesday, July 16th 2014. The company issued 2,016,000 shares at a price of $6.25 per share.

Top institutional shareholders of iRadimed include Hennion & Walsh Asset Management Inc. (0.02%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen, Anthony Vuoto and John Glenn.
View institutional ownership trends
.

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iRadimed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/01/2026
Record date for 5/29 Dividend
5/15/2026
Ex-Dividend for 5/29 Dividend
5/15/2026
Dividend Payable
5/29/2026
Today
7/21/2026
Next Earnings (Estimated)
7/30/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:IRMD
CIK
1325618
Employees
110
Year Founded
2004

Price Target and Rating

High Price Target
$120.00
Low Price Target
$120.00
Potential Upside/Downside
+23.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.83
Trailing P/E Ratio
53.02
Forward P/E Ratio
63.84
P/E Growth
N/A
Net Income
$22.48 million
Net Margins
27.36%
Pretax Margin
34.98%
Return on Equity
24.48%
Return on Assets
21.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.13
Quick Ratio
6.15

Sales & Book Value

Annual Sales
$83.81 million
Price / Sales
14.80
Cash Flow
$1.86 per share
Price / Cash Flow
52.20
Book Value
$7.44 per share
Price / Book
13.04

Miscellaneous

Outstanding Shares
12,780,000
Free Float
8,360,000
Market Cap
$1.24 billion
Optionable
Optionable
Beta
0.90

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:IRMD) was last updated on 7/21/2026 by MarketBeat.com Staff.
From Our Partners